MTHFD2 and cancer: We also show that CRISPR–Cas9 MTHFD2−/− knockout cancer cells and clones are significantly more resistant to TH9619 compared with the parental WT cells, demonstrating that inhibition of MTHFD2 is necessary for the efficacy of TH9619 in cancer cells.